# Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

> **NCT00619619** · PHASE2 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 59 (actual)

## Conditions studied

- Depression
- Major Depressive Disorder

## Interventions

- **DRUG:** Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)

## Key facts

- **NCT ID:** NCT00619619
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-11
- **Final completion:** 2009-11
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2011-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00619619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00619619, "Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00619619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*